Approved and off-label uses of obesity medications, and potential new pharmacologic treatment options
| UDC.coleccion | Investigación | es_ES |
| UDC.endPage | 145 | es_ES |
| UDC.grupoInv | Enfermidades Endocrinas, Nutricionais e Metabólicas (INIBIC) | es_ES |
| UDC.institutoCentro | INIBIC - Instituto de Investigacións Biomédicas de A Coruña | es_ES |
| UDC.issue | 1 | es_ES |
| UDC.journalTitle | Pharmaceuticals | es_ES |
| UDC.startPage | 125 | es_ES |
| UDC.volume | 3 | es_ES |
| dc.contributor.author | Isidro, María Luisa | |
| dc.contributor.author | Cordido, Fernando | |
| dc.date.accessioned | 2023-05-02T07:43:09Z | |
| dc.date.available | 2023-05-02T07:43:09Z | |
| dc.date.issued | 2010-01-12 | |
| dc.description | Review | es_ES |
| dc.description.abstract | [Abstract] Available anti-obesity pharmacotherapy options remain very limited and development of more effective drugs has become a priority. The potential strategies to achieve weight loss are to reduce energy intake by stimulating anorexigenic signals or by blocking orexigenic signals, and to increase energy expenditure. This review will focus on approved obesity medications, as well as potential new pharmacologic treatment options. | es_ES |
| dc.identifier.citation | Isidro ML, Cordido F. Approved and off-label uses of obesity medications, and potential new pharmacologic treatment options. Pharmaceuticals (Basel). 2010 Jan 12;3(1):125-145. | es_ES |
| dc.identifier.issn | 1424-8247 | |
| dc.identifier.uri | http://hdl.handle.net/2183/32966 | |
| dc.language.iso | eng | es_ES |
| dc.publisher | MDPI | es_ES |
| dc.relation.uri | https://doi.org/10.3390/ph3010125 | es_ES |
| dc.rights | Creative Commons Attribution 3.0 International License (CC-BY 3.0) | es_ES |
| dc.rights.accessRights | open access | es_ES |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/ | * |
| dc.subject | Drug treatment | es_ES |
| dc.subject | Ghrelin | es_ES |
| dc.subject | Leptin | es_ES |
| dc.subject | Obesity | es_ES |
| dc.subject | Orlistat | es_ES |
| dc.subject | Sibutramine | es_ES |
| dc.subject | Rimonabant | es_ES |
| dc.title | Approved and off-label uses of obesity medications, and potential new pharmacologic treatment options | es_ES |
| dc.type | journal article | es_ES |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | df28f954-c072-4ef1-b629-d6af3945bd92 | |
| relation.isAuthorOfPublication.latestForDiscovery | df28f954-c072-4ef1-b629-d6af3945bd92 |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- IsidroML_Approved.pdf
- Size:
- 261.41 KB
- Format:
- Adobe Portable Document Format
- Description: